iRhythm Technologies Inc
$ 126.95
-0.78%
05 Mar - close price
- Market Cap 4,134,929,000 USD
- Current Price $ 126.95
- High / Low $ 128.99 / 125.28
- Stock P/E N/A
- Book Value 4.73
- EPS -1.39
- Next Earning Report 2026-04-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE -0.37 %
- 52 Week High 212.00
- 52 Week Low 92.52
About
iRhythm Technologies, Inc., a digital healthcare company, offers ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. The company is headquartered in San Francisco, California.
Analyst Target Price
$212.87
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-10-30 | 2025-07-30 | 2025-04-30 | 2025-02-20 | 2024-10-30 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 0.17 | 0.06 | -0.32 | -0.95 | 0.01 | -1.26 | -0.61 | -1.23 | -1.26 | -0.89 | -0.61 | -1.1 |
| Estimated EPS | 0.01 | -0.32 | -0.5278 | -0.6886 | -0.28 | -0.57 | -0.89 | -0.96 | -0.6 | -0.66 | -0.78 | -0.9 |
| Surprise | 0.16 | 0.38 | 0.2078 | -0.2614 | 0.29 | -0.69 | 0.28 | -0.27 | -0.66 | -0.23 | 0.17 | -0.2 |
| Surprise Percentage | 1600% | 118.75% | 39.371% | -37.9611% | 103.5714% | -121.0526% | 31.4607% | -28.125% | -110% | -34.8485% | 21.7949% | -22.2222% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-30 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.5451 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IRTC
2026-03-04 12:51:45
Short interest in iRhythm Technologies (NASDAQ:IRTC) increased by 20.1% in February, reaching 3.4 million shares, which represents about 10.6% of shares outstanding. Despite this rise in short interest and some insider selling, analyst sentiment for IRTC remains largely positive with a "Moderate Buy" consensus and an average price target of $211.62. The company recently exceeded quarterly earnings and revenue estimates and raised its full-year 2026 revenue guidance, although it still reports a negative net margin.
2026-03-04 10:51:44
Segall Bryant & Hamill LLC reduced its stake in iRhythm Technologies by 8.7% in Q3, selling nearly 12,000 shares but still holding over 125,000 shares valued at $21.55 million. This comes as iRhythm Technologies raised its FY-2026 revenue guidance to $870-$880M, significantly above consensus, and reported strong quarterly earnings. However, the company has seen notable insider selling, with executives disposing of a total of 94,509 shares worth approximately $12.73 million in the past 90 days.
2026-03-04 09:51:44
iRhythm Technologies, Inc. has seen recent stock fluctuations, closing at 133.75, with mixed technical indicators despite outperforming the S&P 500 over the past year. However, the stock has declined by 24.62% year-to-date, indicating short-term struggles. The company, a small-cap player in Pharmaceuticals & Biotechnology, is undergoing an evaluation revision due to these market dynamics.
2026-03-03 23:51:45
iRhythm Holdings, Inc.'s Chief Accounting Officer, Marc Wade Rosenbaum, sold a total of 816 common shares on March 2, 2026. These transactions, consisting of two separate sales, were executed at prices around $128.44-$128.45 per share. The sales were not discretionary but were made to cover tax withholding and remittance obligations related to the vesting of Restricted Stock Units.
2026-03-03 23:51:44
Minang Turakhia, Chief Medical and Scientific Officer of iRhythm Holdings, Inc. (IRTC), sold 4,027 shares of common stock on March 2, 2026, at approximately $128.45 per share. These sales were conducted to cover tax withholding obligations related to the vesting of restricted stock units. Following these transactions, Turakhia retains direct ownership of 54,906 shares of iRhythm common stock.
2026-03-03 10:52:32
Champlain Investment Partners LLC reduced its stake in iRhythm Technologies (NASDAQ:IRTC) by 44.7% in the third quarter, selling 295,605 shares and holding 365,627 shares valued at $62.88 million. Other institutional investors have also adjusted their holdings, while analysts have assigned varied ratings to IRTC, with a consensus of "Moderate Buy" and an average target price of $211.62. The company recently reported earnings of $0.29 per share, significantly beating analyst estimates, and has seen notable insider selling activity.
